|
1
|
Wedd JP, Nordstrom E, Nydam T, Durham J,
Zimmerman M, Johnson T, Purcell Thomas W and Biggins SW:
Hepatocellular carcinoma in patients listed for liver
transplantation: Current and future allocation policy and
management strategies for the individual patient. Liver Transpl.
21:1543–1552. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kuszyk BS, Beauchamp NJ Jr and Fishman EK:
Neurovascular applications of CT angiography. Semin Ultrasound CT
MR. 19:394–404. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kanda M, Sugimoto H and Kodera Y: Genetic
and epigenetic aspects of initiation and progression of
hepatocellular carcinoma. World J Gastroenterol. 21:10584–10597.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Trousseau Armand: Lectures on clinical
medicine, delivered at the Hotel-Dieu, Paris. Translated and edited
with notes and appendices by P. Victor Bazire. Med Clin.
1:1801–1867. 1872.
|
|
5
|
Thodiyil PA and Kakkar AK: Variation in
relative risk of venous thromboembolism in different cancers.
Thromb Haemost. 87:1076–1077. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Blom JW, Vanderschoot JP, Oostindier MJ,
Osanto S, van der Meer FJ and Rosendaal FR: Incidence of venous
thrombosis in a large cohort of 66,329 cancer patients: Results of
a record linkage study. J Thromb Haemost. 4:529–535. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Folkman J: What is the evidence that
tumors are angiogenesis dependent? J National Cancer Institute.
82:4–7. 1990. View Article : Google Scholar
|
|
8
|
Cosmai L, Gallieni M, Liguigli W and Porta
C: Renal toxicity of anticancer agents targeting vascular
endothelial growth factor (VEGF) and its receptors (VEGFRs). J
Nephroll. 30:171–180. 2017. View Article : Google Scholar
|
|
9
|
Wu L, Zhang YS, Ye ML, Shen F, Liu W, Hu
HS, Li SW, Wu HW, Chen QH and Zhou WB: Overexpression and
correlation of HIF-2α, VEGFA and EphA2 in residual hepatocellular
carcinoma following high-intensity focused ultrasound treatment:
Implications for tumor recurrence and progression. Exp Ther Med.
13:3529–3534. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Rong W, Yang L, Yin L, Gao Y, Xiao T and
Cheng S: PSG9 promotes angiogenesis by stimulating VEGFA production
and is associated with poor prognosis in hepatocellular carcinoma.
Sci China Life Sci. 60:528–535. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ghosh A, Dasgupta D, Ghosh A, Roychoudhury
S, Kumar D, Gorain M, Butti R, Datta S, Agarwal S, Gupta S, et al:
miRNA199a-3p suppresses tumor growth, migration, invasion and
angiogenesis in hepatocellular carcinoma by targeting VEGFA,
VEGFR1, VEGFR2, HGF and MMP2. Cell Death Dis. 8:e27062017.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hsu CH, Kang YK, Yang TS, Shun CT, Shao
YY, Su WC, Su WC, Sandoval-Tan J, Chiou TJ, Jin K, et al:
Bevacizumab with erlotinib as first-line therapy in Asian patients
with advanced hepatocellular carcinoma: A multicenter phase II
study. Oncology. 85:44–52. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Meyer G: Venous thromboembolism and
cancer. Rev Prat. 65:216–219. 2015.(In French). PubMed/NCBI
|
|
14
|
Bianconi D, Schuler A, Pausz C,
Geroldinger A, Kaider A, Lenz HJ, Kornek G, Scheithauer W,
Zielinski CC, Pabinger I, et al: Integrin beta-3 genetic variants
and risk of venous thromboembolism in colorectal cancer patients.
Thromb Res. 136:865–869. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kokudo T, Hasegawa K and Kokudo N: Liver,
pancreas, biliary tract cancer. I. Surgical treatment of
hepatocellular carcinoma associated with vascular tumor thrombosis.
Gan To Kagaku Ryoho. 41:1209–1211. 2014.(In Japanese). PubMed/NCBI
|
|
16
|
Posch F, Thaler J, Zlabinger GJ,
Königsbrügge O, Koder S, Zielinski C, Pabinger I and Ay C: Soluble
vascular endothelial growth factor (sVEGF) and the risk of venous
thromboembolism in patients with cancer: Results from the Vienna
cancer and thrombosis study (CATS). Clin Cancer Res. 22:200–206.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Babu Govind K and Bhat GR:
Cancer-associated thrombotic microangiopathy.
Ecancermedicalscience. 10:6492016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Evans CE, Grover SP, Saha P, Humphries J,
Kim JW, Modarai B and Smith A: Suppression of angiogenic response
in local vein wall is associated with reduced thrombus resolution.
Thromb Res. 134:682–685. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Di Vito C, Navone SE, Marfia G, Hadi Abdel
L, Mancuso ME, Pecci A, Crisà FM, Berno V, Rampini P, Campanella R
and Riboni L: Platelets from glioblastoma patients promote
angiogenesis of tumor endothelial cells and exhibit increased VEGF
content and release. Platelets. 28:585–594. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
El-Serag HB: Hepatocellular carcinoma. N
Engl J Med. 365:1118–1127. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yang BH, Xia JL, Huang LW, Tang ZY, Chen
MS, Li JQ, Liang AM, Mo QG, Lu HS, Dai CL, et al: Changes of
clinical aspect of primary liver cancer in China during the past 30
years-control study for 3,250 cases with primary liver cancer.
Zhonghua Yi Xue Za Zhi. 83:1053–1057. 2003.(In Chinese). PubMed/NCBI
|
|
23
|
Karnes RJ and Blute ML: Surgery insight:
Management of renal cell carcinoma with associated inferior vena
cava thrombus. Nat Clin Pract Urol. 5:329–339. 2008.PubMed/NCBI
|
|
24
|
Lambert EH, Pierorazio PM, Shabsigh A,
Olsson CA, Benson MC and McKiernan JM: Prognostic risk
stratification and clinical outcomes in patients undergoing
surgical treatment for renal cell carcinoma with vascular tumor
thrombus. Urology. 69:1054–1058. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lam JS, Klatte T, Kim HL, Patard JJ, Breda
A, Zisman A, Pantuck AJ and Figlin RA: Prognostic factors and
selection for clinical studies of patients with kidney cancer. Crit
Rev Oncol Hematol. 65:235–262. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Squillaci E, Fanucci E, Sciuto F, Masala
S, Sodani G, Carlani M and Simonetti G: Vascular involvement in
pancreatic neoplasm: A comparison between spiral CT and DSA. Dig
Dis Sci. 48:449–458. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chow LC and Rubin GD: CT angiography of
the arterial system. Radiol Clin North Am. 40:729–749. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hakenberg OW: Comment on Di Silverio et
al: Neodajuvant therapy with sorafenib in advanced renal cell
carcinoma with vena cava extension submitted to radical
nephrectomy. Urol Int. 80:4542008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Shuch B, Riggs SB, LaRochelle JC,
Kabbinavar FF, Avakian R, Pantuck AJ, Patard JJ and Belldegrun AS:
Neoadjuvant targeted therapy and advanced kidney cancer:
Observations and implications for a new treatment paradigm. BJU
Int. 102:692–696. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Karakiewicz PI, Suardi N, Jeldres C, Audet
P, Ghosn P, Patard JJ and Perrotte P: Neoadjuvant sutent induction
therapy may effectively down-stage renal cell carcinoma atrial
thrombi. Eur Urol. 53:845–848. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Harshman LC, Srinivas S, Kamaya A and
Chung BI: Laparoscopic radical nephrectomy after shrinkage of a
caval tumor thrombus with sunitinib. Nat Rev Urol. 6:338–343. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Bex A, Van der Veldt AA, Blank C,
Meijerink MR, Boven E and Haanen JB: Progression of a caval vein
thrombus in two patients with primary renal cell carcinoma on
pretreatment with sunitinib. Acta Oncol. 49:520–523. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Roberts E, Cossigny DA and Quan GM: The
role of vascular endothelial growth factor in metastatic prostate
cancer to the skeleton. Prostate Cancer. 2013:4183402013.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Yan JJ, Zhang YN, Liao JZ, Ke KP, Chang Y,
Li PY, Wang M, Lin JS and He XX: miR-497 suppresses angiogenesis
and metastasis of hepatocellular carcinoma by inhibiting VEGFA and
AEG-1. Oncotarget. 6:29527–29542. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhao X, Mohan R, Özcan S and Tang X:
MicroRNA-30d induces insulin transcription factor MafA and insulin
production by targeting mitogen-activated protein 4 kinase 4
(MAP4K4) in pancreatic β-cells. J Biol Chem. 287:31155–31164. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Chen K and Rajewsky N: The evolution of
gene regulation by transcription factors and microRNAs. Nat Rev
Genet. 8:93–103. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
37
|
Lewis BP, Burge CB and Bartel DP:
Conserved seed pairing, often flanked by adenosines, indicates that
thousands of human genes are microRNA targets. Cell. 120:15–20.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Tsai HC, Tzeng HE, Huang CY, Huang YL,
Tsai CH, Wang SW, Wang PC, Chang AC, Fong YC and Tang CH: WISP-1
positively regulates angiogenesis by controlling VEGF-A expression
in human osteosarcoma. Cell Death Dis. 8:e27502017. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Liang Y, Zhao Q, Fan L, Zhang Z, Tan B,
Liu Y and Li Y: Down-regulation of MicroRNA-381 promotes cell
proliferation and invasion in colon cancer through up-regulation of
LRH-1. Biomed Pharmacother. 75:137–141. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Liang HQ, Wang RJ, Diao CF, Li JW, Su JL
and Zhang S: The PTTG1-targeting miRNAs miR-329, miR-300, miR-381,
and miR-655 inhibit pituitary tumor cell tumorigenesis and are
involved in a p53/PTTG1 regulation feedback loop. Oncotarget.
6:29413–29427. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Xu Y, Ohms SJ, Li Z, Wang Q, Gong G, Hu Y,
Mao Z, Shannon MF and Fan JY: Changes in the expression of miR-381
and miR-495 are inversely associated with the expression of the
MDR1 gene and development of multi-drug resistance. PLoS One.
8:e820622013. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Chen B, Duan L, Yin G, Tan J and Jiang X:
Simultaneously expressed miR-424 and miR-381 synergistically
suppress the proliferation and survival of renal cancer cells-Cdc2
activity is up-regulated by targeting WEE1. Clinics (Sao Paulo).
68:825–833. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Rothschild SI, Tschan MP, Jaggi R, Fey MF,
Gugger M and Gautschi O: MicroRNA-381 represses ID1 and is
deregulated in lung adenocarcinoma. J Thoracic Oncol. 7:1069–1077.
2012. View Article : Google Scholar
|
|
44
|
Wu L, Zheng J, Chen P, Liu Q and Yuan Y:
Small nucleolar RNA ACA11 promotes proliferation, migration and
invasion in hepatocellular carcinoma by targeting the PI3K/AKT
signaling pathway. Biomed Pharmacother. 90:705–712. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Hou G, Liu G, Yang Y, Li Y, Yuan S, Zhao
L, Wu M, Liu L and Zhou W: Neuraminidase 1 (NEU1) promotes
proliferation and migration as a diagnostic and prognostic
biomarker of hepatocellular carcinoma. Oncotarget. 7:64957–64966.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Tang Y, Yu H, Zhang L, Wang K, Guo W, Shi
J, Liu S, Wu M, Wang H and Cheng S: Experimental study on
enhancement of the metastatic potential of portal vein tumor
thrombus-originated hepatocellular carcinoma cells using portal
vein serum. Chin J Cancer Res. 26:588–595. 2014.PubMed/NCBI
|
